Scientists investigated whether a novel daily GLP-1/GIP receptor co-agonist treatment would result in type II diabetes remission compared to standard metformin therapy.
The scientists:
The results are shown in the table below:
| Outcome | Group A | Group B |
|---|---|---|
| Percentage achieving diabetes remission | 48.3% | 12.1% |
| Percentage achieving body mass reduction ≥10%\ge 10\%≥10% | 32.4% | 4.5% |
| Percentage with body mass reduction ≥10%\ge 10\%≥10% achieving diabetes remission | 78.5% | 58.2% |
| Percentage with body mass stable or increased achieving diabetes remission | 3.1% | 1.4% |
Calculate the difference in the number of volunteers between the two groups who achieved diabetes remission. Show your working.
